0

Inovio (INO) Receives Authorization For First Human Zika Virus Trial

On Monday Inovio Pharmaceuticals (NASDAQ:INO) and subsidiary Gene One life sciences received authorization to begin the first ever trial in humans for the Zika Virus. This trial will be a phase 1 clinical trial utilizing Inovio’s Zika vaccine candidate, known… Continue Reading

0

Revance Fails Phase 3 Trial; Shares Down 24% In After-Hours

Shares of Revance Therapeutics (NASDAQ:RVNC) fell by 24% in after-hours trade after the company reported that its phase 3 clinical trial failed to meet the primary endpoint. The phase 3 trial was using the company’s drug RT001 to treat patients… Continue Reading

0

Sophiris Bio Closes Up 69% After Successful Phase 2 Prostate Cancer Results

Shares of Sophiris Bio (NASDAQ:SPHS) closed the day up 69% after the company announced that it had received positive phase 2a results in patients with prostate cancer. The phase 2a trial was a proof of concept study to see if… Continue Reading

0

Aduro Biotech Fails Phase 2 Pancreatic Cancer; Shares Fall 16%

Shares of Aduro Biotech (NASDAQ:ADRO) tanked by 16.65% today after the company announced that it had failed its phase 2b “Eclipse” trial in patients with pancreatic cancer. The phase 2b trial was testing the company’s vaccine immunotherapy CRS-207, which is… Continue Reading

0

Rxi Pharmaceuticals Obtains Partnership Agreement For ALS With Thera Neuropharma

On Tuesday May 3, 2016 Rxi Pharmaceuticals (NASDAQ:RXII) announced that it has entered into a license agreement with a privately-held pharmaceutical company known as Thera NeuroPharma. The license agreement expands on the notion that Thera NeuroPharma will use Rxi’s sd-rxRNA… Continue Reading

0

Sarepta’s Eteplirsen Gets Thumbs Down Votes By FDA Advisory Panel

On Monday, an FDA Advisory panel voted down Sarepta Therapeutics (NASDAQ:SRPT) Eteplirsen to treat patients with Duchenne Muscular Dystrophy or DMD. The panel noted concerns with the fact that only 12 patients were recruited in the trial. The truth is that… Continue Reading